In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Legos will take over from Roger Dansey, who will begin transitioning to retirement. Pfizer announced that it has appointed Jeffrey Legos, PhD, MBA, as its new chief oncology officer, succeeding Roger ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

So I think there probably is some risk to that," said Jeff Jonas, portfolio manager for Gabelli Funds, which held about $50 million of Pfizer shares as of September. Analysts expect earnings of 47 ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

However, at least two conditions listed as adverse events also appeared in Pfizer's 2024 list of genuine side effects. In January 2025, Snopes readers asked us about the authenticity of a long ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...